Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization website. http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1. Accessed October 13, 2018.
Martens E, Demain AL. The antibiotic resistance crisis, with a focus on the United States. J Antibiot (Tokyo). 2017;70:520-526.
Fraimow H, Nahra R. Resistant gram-negative infections. Crit Care Clin. 2013;29:895-921.
Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099-1106.
Tamma PD, Goodmen KE, Harris AD, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 2017;64:257-264.
Durante AJ, et al. Expanded susceptibility and resistance mechanism testing among-carbapenem-resistant Enterobacteriaceae in Connecticut, 2017. Presented at: 36^th Annual Conference of the Connecticut Infectious Disease Society (CIDS); May 17, 2018; Orange, CT.
Rosa R, Rudin SD, Rojas LJ, et al. Application of “precision medicine” through the molecular characterization of extensively drug-resistant Klebsiella pneumoniae in a multivisceral transplant patient. Clin Infect Dis. 2017;65:701-702.
Tuite N, Reddington K, Barry T, et al. Rapid nucleic acid diagnostics for the detection of antimicrobial resistance in Gram-negative bacteria: is it time for a paradigm shift? J Antimicrob Chemother. 2014;69:1729-1733. http://jac.oxfordjournals.org/content/early/2014/03/26/jac.dku083.full.pdf. Accessed October 13, 2018.
Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322-2328.
Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108-2113.
Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemo. 2008;61:417-420.
Nation RL, Garonzik SM, Li J, et al. 2016. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis. 2016;62:552-558.
Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis. 2017;64:565-571.
Avery LM, Nicolau DP. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opin Investig Drugs. 2018;27:325-338.
Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61:e01964-e02016.
Kaye KS, Vazquez J, Mathers A, et al. Meropenem-vaborbactam (VABOMERE) vs. best available therapy for CRE infections: TANGO II randomized, controlled phase 3 study results. Poster presented at: IDWeek; October 3-8, 2017; San Diego, CA. Poster 1862.
Wunderink R, Giamarellos-Bourboulis EJ, Rahav G, et al. Meropenem-vaborbactam vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: primary outcomes by site of infection. Poster presented at: IDWeek 2017; October 3-8, 2017; San Diego, CA. Poster 1867.
Connolly LE, Jubb AM, O’Keeffe BO, et al. Plazomicin is associated with improved survival and safety compared to colistin in serious carbapenem-resistant Enterobacteriaceae (CRE) infections: results of the CARE Study. Poster presented at: ASM Microbe; June 1-5, 2017; New Orleans, LA. Poster 571.
Connelly LE, Jubb AM, O'Keefe B, et al. Plazomicin is associated with improved survival and safety compared with colistin in the treatment of serious infections due to carbapenem-resistant Enterobacteriaceae: results of the CARE study. Abstract presented at: 27^th European Congress of Clinical Microbiology and Infectious Diseases; April 22-25, 2027; Vienna, Austria. Abstract OS042 LB.
Motsch J, de Oliveira C, Stus V, et al. A multicenter, randomized, double-blind, comparator-controlled trial comparing the efficacy and safety of imipenem/relebactam versus colistin plus imipenem in patients with imipenem-non-susceptible bacterial infections. Abstract presented at: 28^th European Congress of Clinical Microbiology and Infectious Diseases; April 21-24, 2018; Madrid, Spain. Abstract O0427. http://m.eccmidlive.org/#Abstracts/218389/extend
Rosa R, Rudin SD, Rojas LJ, et al. Application of “precision medicine” through the molecular characterization of extensively drug-resistant Klebsiella pneumoniae in a multivisceral transplant patient. Clin Infect Dis. 2017;65:701-702.
Monogue ML, Abbo LL, Rosa, R, et al. In vitro discordance with in vivo activity: humanized exposures of ceftazidime-avibactam, aztreonam, and tigecycline alone and in combination against New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother. 2017;61:e00486-17.
Marshall S, Hujer AM, Rojas LJ, et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61:e02243-16.
Avery LM, Nicolau DP. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: defining the zone of hope. Int J Antimicrob Agents. 2018;S0924-8579:30202-30204. [Epub ahead of print]
Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014;59:S374-S380.
Lashinsky JN, Henig O, Pogue JM, et al. Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review. Infect Dis Ther. 2017;6:199-211.
Liang W, Liu XF, Haung J, et al. Activities of colistin and minocycline-based combinations against extensive drug resistant Acinetobacter baumanni isolates from intensive care unit patients. BMC Infect Dis. 2011;11:109.
Lin L, Nonejuie P, Munguia J, et al. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant Gram-negative pathogens. EBioMedicine. 2015;2:690-698.
Perez F, Bonomo R. Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria. Lancet Infect Dis. 2018;18:358-360.
Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017;61:e00093- e000117.
Kohira N, West J, Ito A, et al. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains. Antimicrob Agents Chemother. 2015;60:729-734.
Jacobs M, Bajaksouzian S, Good C, et al. In vitro activity of cefiderocol (S-649266), a siderophore cephalosporin, against carbapenem-susceptible and resistant non-fermenting Gram-negative bacteria. Abstract presented at: 28^th European Congress of Clinical Microbiology and Infectious Diseases; April 21-24, 2018; Madrid, Spain. Abstract P0187.
Aoki T, Yoshizawa H, Yamawaki K, et al. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem. 2018;155:847-868.
Sutherland CA, Nicolau DP. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin Therapeutics. 2015;37:1564-1571.
Humphries RM, Hindler JA, Wong-Beringer A, et al. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2017;61:e1858- e1917. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700315. Accessed October 13, 2018.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

David Nicolau, PharmD, FCCP, FIDSA

Director
Center for Anti-Infective Research and Development
Hartford Hospital
Hartford, Connecticut

Disclosures

Disclosure: David Nicolau, PharmD, FCCP, FIDSA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Achaogen, Inc.; Bayer HealthCare; Cepheid; Merck & Co., Inc.; Melinta Therapeutics, Inc.; Pfizer Inc.; Shionogi & Co., Ltd.
Served as a speaker or a member of a speakers bureau for: Achaogen, Inc.; Bayer HealthCare; Cepheid; Merck & Co., Inc.; Melinta Therapeutics, Inc.; Pfizer Inc.; Shionogi & Co., Ltd.
Received grants for clinical research from: Achaogen, Inc.; Bayer HealthCare; Cepheid; Merck & Co., Inc.; Melinta Therapeutics, Inc.; Pfizer Inc.; Shionogi & Co., Ltd.

Panelists

Lilian M. Abbo, MD

Associate Professor of Clinical Infectious Disease
Miller School of Medicine
University of Miami
Miami, Florida

Disclosures

Disclosure: Lilian M. Abbo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Achaogen, Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Merck Sharp & Dohme Corp.; Pfizer Inc.

George Sakoulas, MD

Associate Adjunct Professor
University of California San Diego School of Medicine
Infectious Disease Consultant
Sharp Healthcare
La Jolla, California

Disclosures

Disclosure: George Sakoulas, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Arsanis, Inc.; Cidara Therapeutics, Inc.; Melinta Therapeutics, Inc.; Nabriva Therapeutics plc
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Melinta Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.

Editor

Susan L. Smith, MN, PhD

Lead Scientific Director, Medscape, LLC

Disclosures

Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CME / ABIM MOC

The Race Against MDROs: Strategies for Pulling Ahead of Serious Bacterial Infections

Authors: David Nicolau, PharmD, FCCP, FIDSA; Lilian M. Abbo, MD; George Sakoulas, MD
CME / ABIM MOC Released: 11/19/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/19/2019

Start Activity

Target Audience and Goal Statement

This activity is intended for infectious disease/HIV specialists, primary care physicians, and critical care specialists.

The goal of this activity is to inform clinicians of antibiotic stewardship and how to identify and treat patients at greatest risk for infections caused by multidrug-resistant organisms.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Ongoing challenge of serious bacterial infections and emerging resistance
Have greater competence related to
- The recognition of patient populations at increased risk for morbidity and mortality from serious bacterial infections
- Strategies to address the unique needs of special populations at increased risk for morbidity and mortality
- Timely and appropriate incorporation of agents that individualize patient care needs and support antibiotic stewardship

Disclosures

Moderator

David Nicolau, PharmD, FCCP, FIDSA

Director
Center for Anti-Infective Research and Development
Hartford Hospital
Hartford, Connecticut

Disclosures

Disclosure: David Nicolau, PharmD, FCCP, FIDSA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Achaogen, Inc.; Bayer HealthCare; Cepheid; Merck & Co., Inc.; Melinta Therapeutics, Inc.; Pfizer Inc.; Shionogi & Co., Ltd.
Served as a speaker or a member of a speakers bureau for: Achaogen, Inc.; Bayer HealthCare; Cepheid; Merck & Co., Inc.; Melinta Therapeutics, Inc.; Pfizer Inc.; Shionogi & Co., Ltd.
Received grants for clinical research from: Achaogen, Inc.; Bayer HealthCare; Cepheid; Merck & Co., Inc.; Melinta Therapeutics, Inc.; Pfizer Inc.; Shionogi & Co., Ltd.

Panelists

Lilian M. Abbo, MD

Associate Professor of Clinical Infectious Disease
Miller School of Medicine
University of Miami
Miami, Florida

Disclosures

Disclosure: Lilian M. Abbo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Achaogen, Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Merck Sharp & Dohme Corp.; Pfizer Inc.

George Sakoulas, MD

Associate Adjunct Professor
University of California San Diego School of Medicine
Infectious Disease Consultant
Sharp Healthcare
La Jolla, California

Disclosures

Disclosure: George Sakoulas, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Arsanis, Inc.; Cidara Therapeutics, Inc.; Melinta Therapeutics, Inc.; Nabriva Therapeutics plc
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Melinta Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.

Editor

Susan L. Smith, MN, PhD

Lead Scientific Director, Medscape, LLC

Disclosures

Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Infectious Diseases

CME / ABIM MOC

The Race Against MDROs: Strategies for Pulling Ahead of Serious Bacterial Infections

Authors: David Nicolau, PharmD, FCCP, FIDSA; Lilian M. Abbo, MD; George Sakoulas, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/19/2018

Valid for credit through: 11/19/2019

processing....

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

David Nicolau, PharmD, FCCP, FIDSA

Panelists

Lilian M. Abbo, MD

George Sakoulas, MD

Editor

Susan L. Smith, MN, PhD

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

CME / ABIM MOC

The Race Against MDROs: Strategies for Pulling Ahead of Serious Bacterial Infections

Target Audience and Goal Statement

Disclosures

Moderator

David Nicolau, PharmD, FCCP, FIDSA

Panelists

Lilian M. Abbo, MD

George Sakoulas, MD

Editor

Susan L. Smith, MN, PhD

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Race Against MDROs: Strategies for Pulling Ahead of Serious Bacterial Infections